A molecular subgroup has been identified which is characterised by upregulation of Receptor Tyrosine Kinases (RTKs) and the MAPK pathway, leading to increased Epithelial to Mesenchymal Transition (EMT) and angiogenesis. The subgroup exists across multiple diseases and patients within it demonstrate poor prognosis across multiple cancers, including breast, lung, colon, renal, pancreatic, stomach, bladder, ovarian, melanoma and glioblastoma.
A 15 gene signature has been developed to prospectively identify patients which fall into the EMT molecular subgroup from formalin-fixed paraffin-embedded (FFPE) tissue and can be used to select patients for:
- MAPK targeted therapies (for example: MEK, p38 inhibitors)
- EMT targeted therapies (for example: AXL inhibitors)
- RTK targeted therapies (for example: Tyrosine kinase inhibitors)
Assessment of the Almac EMT Assay can be made through use of Almac Diagnostic Services unique gene expression report, claraT.This provides visualisation of the EMT Assay scores as an easy-to-interpret graduated bar.